Confirmed Invited Speakers

Participants from many countries have already confirmed their presence, including Czech Republic, Poland, Hungary, Slovakia, France, United Kingdom, Denmark, Romania, Turkey, Bosnia and Herzegovina, Germany, Serbia, Japan, China, Italy, Brazil, USA, Canada, etc.

NameCountryTitle of the presentation
R. FischmeisterParis, FrancePhosphodiesterase type 2: a new target in heart failure?
G. HeuschEssen, GermanyCoronary microvascular injury by ischemia/reperfusion and protection from it.
M.S. SuleimanBristol, UKTribulations of moving from bench to bedside to mend broken heart.
L. KirshenbaumWinnipeg, CanadaInnate immunity signaling in doxorubicin cardiomyopathy.
F. GallyasPecs, HungaryRepurposing of PARP inhibitors for cardiovascular diseases.
M. CzubrytWinnipeg, CanadaFibroblast activation as a therapeutic target for cardiac fibrosis.
M. HlavackovaPrague, Czech RepublicExploring Hif-1α and epitranscriptomic regulation in diabetic cardiomyopathy.
M. MichalakEdmonton, CanadaInterplay between stress sensors and cardiac excitation-contraction coupling.
H. S. ButtarOntario, CanadaThe crucial roles of healthful foods, healthy hut microbiomes, and lifestyle modifications in preventing cardiovascular diseases.
M. DelmarNew York, USASudden cardiac arrest in young athletes:  the case of ARVC.
D. M. DjuricBelgrade, Republic of SerbiaComparison of the cardioprotective effects of folic acid in homocysteine-dependent and homocysteine-independent cardiometabolic disease models.
N. NagySzeged, HungaryInvestigation of action potential alternans in normal and failed human heart.
P. BencsikSzeged, HungaryTherapeutic use of ProtectomiRs (cardioprotective microRNAs) against myocardial ischemia/reperfusion injury.
N. JostSzeged, HungaryThe invetsigation of the antiarrhythmic effects of novel amiodarone-like mexiletine analogue compounds.
A. J. MarianTexas, USADNA double-stranded breaks in the pathogenesis of heart failure.
R. BolliKentucky, USACurrent status of cardioprotection, gene therapy, and cell therapy for heart disease.
P. FerdinandyBudapest, HungaryDeveloment of miRNA therapeutics for cardiprotection.
V. JakovljevicKragujevac, Republic of SerbiaUsnic acid as a new protector against doxorubicin-induced cardiotoxicity in rats.
N. S. DhallaWinnipeg, CanadaRole of Renin-angiotensin system in the loss of adrenergic support in heart failure.
B. OstadalPrague, Czech RepublicSex differences in cardiac tolerance to oxygen deprivation - 40 years of cardiovascular research.
I. BaczkoSzeged, HungaryAtrial and ventricular arrhythmogenic remodeling in a large animal model of athlete's heart.
A. VarroSzeged, HungaryImportant species differences in cardiac electrophysiology.
M. MoradSouth Carolina, USARegulation of sarco-tubular, mitochondrial, and nuclear-envelop calcium signaling in human stem-cell derived cardiomyocytes.
G. LopaschukEdmonton, CanadaTargeting cardiac fatty acid oxidation to treat heart failure with preserved ejection fraction (HFpEF).
I. Rabinovich-NikitinWinnipeg, CanadaThe effects of shift work on cardiovascular health during pregnancy.
S. DhingraWinnipeg, CanadaImmunomodulation of allogeneic stem cells for cardiac repair.
D. AgrawalCalifornia, USAImmune mediators and modulators in reducing size and inducing stability of atherosclerotic plaques in carotid artery: novel treatment Strategies.
S. TyagiKentucky, USAThe role of the circadian clock system in the transition of HFpEF to the HFrEF.
S. TipparajuFlorida, USANampt activation for protecting the diabetic heart.
M. BartekovaBratislava, SlovakiaNatural polyphenol quercetin as a potential cardioprotective tool for preventing ischemia-reperfusion injury.
P. KleinbongardEssen, GermanyCardioprotection by remote conditioning - an update on the signal transduction pathways.
S. OhtaTokyo, JapanHydrogen medicine from the basic science to clinical trials
J. NeckarCzech RepublicExperimental rat models of HFpEF.
P. KrenekSlovakiaEndothelin system in experimental pulmonary hypertension.